API | metaiodobenzylguanidine

metaiodobenzylguanidine Report issue

Small molecule Imaging Experimental

AACT PubChem

Active Ingredient History

NOW

Iobenguane, or MIBG, is an aralkylguanidine analog of the adrenergic neurotransmitter norepinephrine (noradrenaline), typically used as a radiopharmaceutical. It acts as a blocking agent for adrenergic neurons. When radiolabeled, it can be used in nuclear medicinal diagnostic and therapy techniques as well as in neuroendocrine chemotherapy treatments. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Imaging: 124-iodine
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

124i-mibg | metaiodobenzylguanidine | mibg

Organizations (10)

Research & Development (10)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (1)

Neuroblastoma

Experimental Indications - Clinical Trial Phases 1-4 (8)

Cognitive Dysfunction (Phase 4)

Dementia (Phase 4)

Lewy Body Disease (Phase 4)

Neoplasm Metastasis (Early Phase 1)

Neoplasms (Phase 2)

Neuroblastoma (Phase 2)

Parkinsonian Disorders (Phase 4)

REM Sleep Behavior Disorder (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial Organizations: 10

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue